NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01516580,Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients,https://clinicaltrials.gov/study/NCT01516580,,UNKNOWN,"The aim of the trial is to test whether adding 6 injections of rituximab to standard ""Lymphome malin B"" LMB chemotherapy regimen improves the Event Free Survival (EFS) compared with LMB chemotherapy alone in children / adolescents with advanced stage B-cell Non-Hodgkin Lymphoma (NHL) / B-Acute Leukemia (B-AL)(stage III and LDH \> Nx2, any stage IV or B-AL).",NO,B-cell Non Hodgkin Lymphoma|Mature B-cell Leukemia Burkitt-type,"DRUG: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|DRUG: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C","Event free survival, Minimum time to death from any cause, presence of viable cells in residue after \[2nd (Rituximab-)CYVE\], relapse, progressive disease, or second malignancy measured from randomization., 24 months","Survival, Overall survival, 5 years|Acute toxicity, Acute toxicity during treatment according to NCI-CTC V4, 6 months|Long term toxicity, Long term toxicity, especially immune reconstitution, cardiac toxicity, 5 years",,"Gustave Roussy, Cancer Campus, Grand Paris",Children's Oncology Group,ALL,CHILD,PHASE3,482,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,Inter B-NHL Ritux 2010 Phase 3|2010-019224-31,2011-12,2017-06-13,2021-12,2012-01-25,,2017-06-14,"University Hospitals Leuven, Leuven, 3000, Belgium|Children Oncology Group Operations centres, Monrovia, Canada|The University of Hong Kong (Clinical Trials Centre), Hong-Kong, China|Institut de Cancérologie Gustave roussy, Villejuif, 94805, France|2nd Dept. of Pediatrics Semmelweis Univ., Budapest, 1094, Hungary|Associazione Italiana di Ematologia ed Oncologia Pediatrica, Padova, 35128, Italy|Emma Children's Hospital, Amsterdam, 1105 AZ, Netherlands|Rectorat of Medical University, Wroclaw, Poland|Sociedad Española de Hematología y Oncología Pediátricas, Valencia, 46010, Spain|University of Birmingham, Birmingham, United Kingdom",
